A study investigating rivaroxaban to assess various outcomes of cancer patients with blood clots who are treated with an anticoagulant to better understand the treatment of VTE and the prevention of recurrent events in this patient population
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2015
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Cancer; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms CALLISTO
- 07 Dec 2015 According to a Janssen Pharmaceuticals media release, results from first 200 patients were presented at the 2015 American Society of Hematology (ASH) Annual Meeting.
- 07 Dec 2015 Results from first 200 patients were published in a Janssen Pharmaceuticals media release.
- 07 Dec 2015 Status changed from planning to recruiting, according to a Janssen Pharmaceuticals media release.